IP Library › Granted Patent US 12,253,524
Granted Patent B2
US 12,253,524 · App. 18/131,559 · Granted Mar 18, 2025

Methods and compositions for determining the functional activity of DNA double strand break repair pathway molecules for assessing germline risk of cancer

Inventors: Harry Ostrer (New York, NY); Johnny C. Loke (Nanuet, NY); Alexander Pearlman (New York, NY)
Assignee: Albert Einstein College of Medicine
G01N33/57496C12Q1/6886G01N33/57415G01N33/57449G01N33/57484C12Q2600/156G01N2333/4703G01N2333/4748G01N2333/9108G01N2440/14G01N2800/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,253,524
App. No.
18/131,559
Granted
Mar 18, 2025
Kind
B2
Abstract

Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1 complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.

Claims (27)

1. A method comprising:

obtaining circulating white blood cells from a subject;

treating the white blood cells with a DNA damaging agent;

performing a flow cytometry based functional variant analysis (FVA);

measuring in the treated cell at least one functional activity of a DNA double strand break (DSB) repair pathway gene comprising ATM, BRCA1, BRCA2, PALB2, FANCD2, FANCC, FANCF, NBN, BARD1, p53, RAD50/51, NBS1, Abraxas, CtIP, and DNA Ligase genes;

comparing the at least one measured functional activity with at least one control value obtained from control white blood cells treated with the DNA damaging agent and having a wild type DNA double strand break (DSB) repair pathway; and

categorizing DSB repair pathway gene in the subject as functional, having loss of function or having a gain of function, based on the comparing step, wherein the DSB repair pathway gene comprises ATM, BRCA1, BRCA2, PALB2, FANCD2, FANCC, FANCF, NBN, BARD1, p53, RAD50/51, NBS1, Abraxas, CtIP, and DNA Ligase genes.

2. The method of claim 1 , wherein the at least one functional activity is selected from the group consisting of BRCA1 nuclear localization, BRCA2 nuclear localization, BRCA1 binding to a partner selected from the group consisting of PALB2, BRCA2 and FANCD2, and phosphorylation of p53.

3. The method of claim 1 , wherein said at least one control value is measured from normal white blood cells or white blood cells having a normal DNA DSB repair pathway.

4. The method of claim 1 , wherein said at least one control value is measured from white blood cells with a defective DNA DSB pathway and cancer risks.

5. The method of claim 1 , wherein said at least one control value is established at an earlier time.

6. The method of claim 1 , wherein said at least one control value is established in parallel to the measurement of the functional activity of the DSB repair pathway in the white blood cells from said subject.

7. The method of claim 1 , wherein said white blood cells are selected from the group consisting of B cells, lymphoblastoid cells and total white blood cells.

8. The method of claim 1 , where the white blood cells are cultured prior to treatment with a DNA damaging agent.

9. The method of claim 1 , wherein the DNA damaging agent is selected from radiation, a chemical compound, or a combination thereof.

10. The method of claim 9 , wherein said radiation is UV, x-ray or gamma-ray.

11. The method of claim of claim 10 , wherein said compound is selected from the group consisting of Mitomycin C (MMC), 1,3-butadiene diepoxide (DEB), Bleomycin (Bleo), or a combination thereof.

12. The method of claim 1 , wherein said at least one functional activity of a DNA double strand break (DSB) repair pathway gene being measured is BRCA1 nuclear localization or BRCA2 nuclear localization.

13. The method of claim 12 , wherein BRCA1 nuclear localization or BRCA2 nuclear localization is measured in an assay using one DNA damaging agent.

14. The method of claim 12 , wherein BRCA1 nuclear localization or BRCA2 nuclear localization is measured in multiple assays each using a different DNA damaging agent.

15. The method of claim 12 , wherein BRCA1 nuclear localization or BRCA2 nuclear localization is measured using a DCW (digital cell Western)-nuclear localization assay format.

16. The method of claim 15 , wherein the DCW-nuclear localization assay comprises fixing the treated cells,

subjecting the treated cells to cell lysis conditions that causes lysis of a predetermined percentage of cells,

collecting the nuclei and unlysed cells by centrifugation,

resuspending the collected nuclei and unlysed cells in a staining buffer comprising an optically active agent-conjugated anti-BRCA1 antibody or an optically active agent-conjugated anti-BRCA2 antibody and an optically active agent-conjugated antibody specific for a protein localized intracellularly and outside of the nucleus,

measuring the amount of BRCA1 protein localized to the nuclei and the total amount of BRCA1 protein in the cells, and

determining the ratio of the amount of BRCA1 protein or BRCA2 protein localized to the nuclei versus the total amount of BRCA1 protein expressed in the cells as basis of determining said functional activity of BRCA1 or said functional activity of BRCA2.

Continuity (4)
Continuation 16900194 · Jun 12, 2020
Continuation 15504726
Provisional Application 62039691 · Aug 20, 2014
Related Publication 20230258646A1 · Aug 17, 2023
References Cited (50)
US 10718774B2 · Ostrer et al. · 2020 [cited by applicant]
US 20140017678A1 · Cesano et al. · 2014 [cited by applicant]
US 20140194315A1 · Loke et al. · 2014 [cited by applicant]
EP 3183360B1 · 2019 [cited by applicant]
WO 2016028870A1 · 2016 [cited by applicant]
Bogdanova N. et al., “Nigmegen Breakage Syndrome Mutations and Risk of Breast Cancer”, Int. J. Cancer 122:802-806 (2008). [cited by applicant]
Bouwman P. et al., “A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants”, Cancer Discovery 3:1142-1155 (Oct. 2013). [cited by applicant]
Carvalho M.A. et al., “Determination of Cancer Risk Associated With Germ Line BRCA1 Missense Variants by Functional Analysis”, Cancer Research 67(4):1494-1501 (Feb. 15, 2007). [cited by applicant]
Carvalho M.A. et al., “Functional Assays for BRCA1 and BRCA2”, Int J Biochem Cell Biol. 39(2):298-310 (2007). [cited by applicant]
Casadei S. et al., “Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer”, Cancer Research 71(6):2222-2229 (Mar. 15, 2011). [cited by applicant]
Castilla L.H. et al., “Mutations in the BRCA1 Gene in Families With Early-Onset Breast and Ovarian Cancer”, Nature Genetics 8:387-391 (Dec. 1994). [cited by applicant]
Chang S. et al., “Tumor Suppressor BRCA1 Epigenetically Controls Oncogenic MicroRNA-155”, Nature Medicine 17(10):1275-1282 (Oct. 2011). [cited by applicant]
Chen J. et al., “Stable Interaction Between the Products of the BRCA1 and BRCA2 Tumor Suppressor Genes in Mitotic and Meiotic Cells”, Molecular Cell 2:317-328 (Sep. 1998). [cited by applicant]
Chinese Office Action dated May 29, 2020 in Chinese Patent Application No. 201580050654.8, together with an English-language translation. [cited by applicant]
Chinese Office Action dated Feb. 23, 2021 received in Chinese Patent Application No. 201580050654.8, together with an English-language translation. [cited by applicant]
Desjardins S. et al., “Variations in the NBN/NBSI Gene and the Risk of Breast Cancer in Non-BRCAI/2 French Canadian Families With High Risk of Breast Cancer”, BMC Cancer 9:181 (Jun. 2009). [cited by applicant]
Examination Search Report dated Jul. 29, 2022 received in CA Application No. 2,958,550, 3 pages. [cited by applicant]
Friedman L.S. et al., “Confirmation of BRCA1 By Analysis of Germline Mutations Linked to Breast and Ovarian Cancer in Ten Families”, Nature Genetics 8:399-404 (Dec. 1994). [cited by applicant]
Gorski B. et al., “Founder Mutations in the BRCA1 Gene in Polish Families With Breast-Ovarian Cancer”, Am. J. Hum. Genet. 66:1963-1968 (2000). [cited by applicant]
Gowen L.C. et al., “Brca1 Deficiency Results in Early Embryonic Lethality Characterized by Neuroepithelial Abnormalities”, Nature Genetics 12:191-194 (Feb. 1996). [cited by applicant]
Hakem R. et al., “The Tumor Suppressor Gene Brca1 is Required for Embryonic Cellular Proliferation in the Mouse”, Cell 85:1009-1023 (Jun. 28, 1996). [cited by applicant]
Heikkinen K. et al., “RAD50 and NBS1 are Breast Cancer Susceptibility Genes Associated With Genomic Instability”. Carcinogenesis 27(8):1593-1599 (2006). [cited by applicant]
Hsu H-M et al., “Breast Cancer Risk is Associated With the Genes Encoding the DNA Double-Strand Break Repair Mre11/Rad50/Nbs1 Complex”, Cancer Epidemiol Biomarkers Prev 16(10):2024-2032 (2007). [cited by applicant]
Jara L. et al., “Molecular Analysis of the Eighteen Most Frequent Mutations in the BRCA1 Gene in 63 Chilean Breast Cancer Families”, Biol Res 37:469-481 (2004). [cited by applicant]
Lee M.S. et al., “Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays”, Cancer Research 70(12):4880-4890 (Jun. 15, 2010). [cited by applicant]
Loke J. et al., “Mutations in MAP3K1 Tilt the Balance from SOX9/FGF9 to WNT/B-Catenin Signaling”, Human Molecular Genetics 23(4):1073-1083 (2014). [cited by applicant]
Loke J. et al., “Rapidly Screening Variants of Uncertain Significance in the MAP3K1 Gene for Phenotypic Effects”, Clinical Genetics 81:272-277 (2012). [cited by applicant]
Mannucci A. et al., “Biomass Accumulation Modelling in a Highly Loaded Biotrickling Filter for Hydrogen Sulphide Removal”, Chemosphere 88:712-717 (2012). [cited by applicant]
Murray M.L. et al., “Follow-Up of Carriers of BRCA1 and BRCA2 Variants of Unknown Significance, Variant Reclassification and Surgical Decisions”, Genetics in Medicine 13(12):998-1005 (Dec. 2011). [cited by applicant]
Scully R. et al., “Association of BRCA1 With Rad51 in Mitotic and Meiotic Cells”, Cell 88:265-275 (Jan. 24, 1997). [cited by applicant]
Seal S. et al., “Truncating Mutations in the Fanconi Anemia J Gene BRIP1 are Low-Penetrance Breast Cancer Susceptibility Alleles”, Nature Genetics 38(11):1239-1241 (Nov. 2006). [cited by applicant]
Serova O. et al., “A High Incidence of BRCA1 Mutations in 20 Breast-Ovarian Cancer Families”, Am. J. Hum. Genet. 58:42-51 (1996). [cited by applicant]
Stacey S.N. et al., “The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland”, PLoS Medicine 3(7):1103-1113 (Jul. 2006). [cited by applicant]
Starita L.M. et al., “Substrates of the BRCA1-Dependent Ubiquitin Ligase”, Cancer Biology & Therapy 5(2):137-141 (Feb. 2006). [cited by applicant]
Struewing J.P. et al., “Detection of Eight BRCAI Mutations in 10 Breast/Ovarian Cancer Families, Including I Family With Male Breast Cancer”, Am. J. Hum. Genet. 57:1-7 (1995). [cited by applicant]
Struewing J.P. et al., “The Carrier Frequency of the BRCA1 185delAG Mutation is Approximately 1 Percent in Ashkenazi Jewish Individuals”, Nature Genetics 11:198-200 (Oct. 1995). [cited by applicant]
Tonin P. et al., “Frequency of Recurrent BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Families” Nature Medicine 2(11):1179-1183 (Nov. 1996). [cited by applicant]
Venkitaraman A.R., “Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2”, Science 343:1470-1475 (Mar. 28, 2014). [cited by applicant]
Venkitaraman A.R., “Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment”, Annu. Rev. Pathol. Mech. Dis. 4:461-487 (2009). [cited by applicant]
Wang Y. et al., “BASC, a Super Complex of BRCA1-Associated Proteins Involved in the Recognition and Repair of Aberrant DNA Structures”, Genes and Development 14:927-939 (2000). [cited by applicant]
International Search Report dated Nov. 24, 2015 issued in PCT/US2015/045856. [cited by applicant]
Huen et al., “BRCA1 and its toolbox for the maintenance of genome integrity”, Nat Rev Mol Cell Biol. (Feb. 2010), vol. 11, No. 2, pp. 138-148. [cited by applicant]
Becker A.A. et al., “A 24-Color Metaphase-Based Radiation Assay Discriminates Heterozygous BRCA2 Mutation Carriers from Controls by Chromosomal Radiosensitivity”, Breast Cancer Res Treat 135:167-175 (2012). [cited by applicant]
Febrer E. et al., “Mitotic Delay in Lymphocytes from BRCA1 Heterozygotes Unable to Reduce the Radiation-Induced Chromosomal Damage”, DNA Repair 7:1907-1911 (2008). [cited by applicant]
Trenz K. et al., “Mutagen Sensitivity of Peripheral Blood from Women Carrying a BRCA1 or BRCA2 Mutation”, Mutation Research 500:89-96 (2002). [cited by applicant]
Vilasova Z. et al., “Changes in Phosphorylation of Histone H2A.X and p53 in Response of Peripheral Blood Lymphocytes to Gamma Irradiation”, Acta Biochimica Polonica 55(2):381-390 (2008). [cited by applicant]
Extended Supplementary European Search Report dated Feb. 9, 2018 received in European Patent Application No. 15 83 3376.5. [cited by applicant]
European Office Action dated Nov. 15, 2018 issued in EP 15 833 376.5. [cited by applicant]
Keimling M. et al., “The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility”, The FASEB Journal, (2012), vol. 26, No. 5, pp. 2094-2104. [cited by applicant]
Syeda M.M. et al., “Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells”, Genetics in Medicine, (2017), 7 pages doi:10.1038/gim.2016.222. [cited by applicant]